|Bid||4.4100 x 800|
|Ask||5.2900 x 800|
|Day's Range||4.5400 - 4.7100|
|52 Week Range||4.4700 - 76.8100|
|Beta (5Y Monthly)||0.77|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 30, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||59.79|
Today is shaping up negative for I-Mab ( NASDAQ:IMAB ) shareholders, with the analysts delivering a substantial...
I-Mab's (IMAB) partner AbbVie decides to stop early-stage development of an anti-CD47 antibody therapy targeting multiple cancer indications. IMAB intends to support the candidate's development.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...